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Abstract: Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia. The 
prevalence of AF increases sharply in old age (prevalence approximately 10% among persons 
80 years of age and older). The expected risk for ischemic stroke is increased five-fold by the 
presence of AF, primarily as a result of cardiogenic embolism. Multiple large-scale, randomized 
trials have been completed or are still underway to find optimal, efficacious, and relatively safe 
ways to reduce the risk of ischemic stroke and other systemic thromboembolic events related to 
AF. Antithrombotic strategies are accompanied by serious bleeding complications that threaten 
patients in need of medical stroke prevention. Treatment regimens for preventing thromboembo-
lism in AF patients range from vitamin K antagonists such as warfarin or coumadins, antiplatelet 
drugs like aspirin or clopidogrel, to newly developed orally available antithrombotics like the 
direct thrombin inhibitor dabigatran, or the Factor Xa-inhibitor rivaroxaban. The available 
anticoagulant and antiplatelet drugs have different advantages and disadvantages. This review 
attempts to delineate the specific role of clopidogrel in patients with AF and at risk of stroke, 
taking into consideration new and ongoing trials in this important field of medical practice.
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Introduction
Atrial fibrillation (AF) is the most common cardiac rhythm disorder and an important 
independent risk factor for ischemic stroke. AF affects nearly 2.5 million people in 
the US (approximately 1%). The prevalence of this arrhythmia increases sharply with 
older age. Worldwide population trends of increasing life expectancy and increasing 
prevalence of known risk factors for AF indicate a worsening epidemic of the condi-
tion.1 AF is uncommon among individuals 50 years of age. In the Framingham 
Heart Study, the percentage risk of stroke ascribable to AF rose from 1.5% in the 
age group 50 to 59 years, to 23.5% in the age group 80 to 89 years. The median age 
of patients with AF is 72 years. Overall, AF accounts for about 15% of all strokes 
in the US.2 The rate of ischemic stroke among patients with AF included in primary 
prevention clinical trials and not treated with antithrombotic therapy averaged 4.5% 
per year, similar to estimates of stroke risk from the Framingham Heart Study. Further 
analyses from these studies indicate that the lifetime risk of AF for an individual aged 
40 years is about 25%.3 The occurrence of AF may be even higher given the potential 
for AF to remain undiagnosed.
AF is more prevalent in men than in women at all ages. AF raises the risk of 
  ischemic stroke four- to five-old, predominantly as the result of cardiogenic embolism.4 
This is based on clinical assessment, by extension of operative findings of intracardiac Vascular Health and Risk Management 2010:6 96
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thrombus in patients with rheumatic mitral valve disease 
and, more recently, by transesophageal echocardiographic 
imaging of thrombus in the left atrium of patients with AF, 
mainly in the left atrial appendage.5
Given the epidemiologic characteristics of AF and the 
importance of stroke as a leading cause of death and disabil-
ity, multiple large-scale, randomized trials have been com-
pleted, or are underway, to find effective and relatively safe 
ways to reduce the risk of ischemic stroke and other systemic 
thromboembolic events related to AF. Antagonists of vitamin 
K have been used as anticoagulants for over 50 years. Warfa-
rin, a synthetic derivative of coumarin, is the most commonly 
used vitamin K antagonist (VKA) in the US. In most Euro-
pean countries, other coumarin derivatives (phenprocoumon 
and acenocoumarol) are used as an alternative to warfarin. 
Vitamin K is essential for the hepatic synthesis of Factors 
II (prothrombin), VII, IX, and X, as well as protein C and 
protein S.6 With appropriate dosing, these medications effec-
tively inhibit coagulation and have been shown to reduce 
substantially the risk of stroke in AF and the likelihood of 
recurrence of venous thromboembolism (VTE).7,8 However, 
VKAs are limited by a narrow therapeutic window as well 
as the need for frequent coagulation monitoring and dosage 
adjustments. Other drawbacks of this class include drug 
and food interactions (eg, foods rich in vitamin K), a well 
documented incidence of major bleeding of 1% to 3%, and 
delayed onset and offset of anticoagulant effect.9 However, 
in spite of their considerable limitations, VKAs have been 
the standard of care for long term prophylaxis of stroke in 
patients with AF.
Newly acquired data on alternative antithrombotic 
  strategies might change this. The recently presented RE-LY 
trial, which compared the direct thrombin inhibitor dabiga-
tran with warfarin, has the potential to set a new landmark 
in the prevention of stroke, thromboembolic complications, 
and reduction of life-threatening hemorrhagic complications. 
In patients with AF, dabigatran given at a dose of 110 mg 
twice daily was associated with rates of stroke and  sys-
temic embolism that were similar to those associated with 
  warfarin, as well as lower rates of major hemorrhage. 
Dabigatran administered at a dose of 150 mg twice daily, 
as compared with warfarin, was associated with lower rates 
of stroke and systemic embolism but similar rates of major 
  hemorrhage.10
Antiplatelet drugs such as acetylsalicylic acid (ASA), 
ticlopidine, dipyridamole, and clopidogrel play an important 
role in stroke prevention for patients with AF for various 
reasons and in specific indications. The purpose of this review 
is to elucidate the role of one of these antiplatelet drugs, 
clopidogrel, in stroke prevention for patients suffering from 
AF. We also focus on alternative antiaggregation therapies 
and their advantages and disadvantages.
Pharmacology, pharmacokinetics, 
and mode of action
Platelets are important in the initiation and progression of 
thrombus formation leading to thromboembolic obstruc-
tion of brain-supplying arterial blood vessels in patients 
with transient ischemic attack (TIA) and ischemic stroke. 
  Antiplatelet agents have been confirmed in randomized tri-
als as a cornerstone for medical stroke prevention in patients 
with TIA/stroke of non-cardioembolic etiology.
Clopidogrel is a prodrug administered orally. It is rapidly 
absorbed from the gastrointestinal tract with a bioavail-
ability of about 50%.11 It is 98% bound to plasma proteins. 
The half-life of its active metabolite is approximately eight 
hours. Approximately 85% of the prodrug is hydrolyzed 
by esterases in the blood to an inactive carboxylic acid 
derivative, and only 15% of the prodrug is metabolized by 
the cytochrome P450 (CYP450) system in the liver to gener-
ate an active metabolite.12 The effect of liver disease on the 
antiplatelet activity of clopidogrel has not been thoroughly 
investigated. The active metabolite, a carboxylic acid deriva-
tive, irreversibly inhibits the adenosine diphosphate P2Y12 
receptor. Activation of the P2X1 and P2Y1 receptors leads 
to alteration in shape and initiates a weak and transient phase 
of platelet aggregation. The P2X1 mediates extracellular 
calcium influx and utilizes adenosine triphosphate as an 
agonist (see Figure 1). Thienopyridines (such as clopidogrel 
or ticlopidine) bind highly selectively to the P2Y12-receptor 
on the surface of platelets. This binding is irreversible and 
therefore platelets exposed to thienopyridines are inhibited 
for their life spans.13 Therefore it takes 5–7 days to restore 
platelet function completely. This must be considered if 
clopidogrel is used in patients in whom invasive or surgical 
treatment is planned.
Given that ticlopidine has been associated with a high 
incidence of adverse events, clopidogrel has become the 
drug of choice.14 After repeated daily dosing with clopidogrel 
75 mg, steady-state is achieved after 4–7 days. If a more 
rapid antiplatelet effect is required, a loading dose of 300 mg 
clopidogrel followed by a daily dose of 75 mg is needed. The 
efficacy of higher loading doses such as 600 mg or 900 mg 
need to be further investigated. At steady-state, clopidogrel 
inhibits 50% to 60% of platelet aggregation induced by 
adenosine diphosphate.15Vascular Health and Risk Management 2010:6 97
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Efficacy of clopidogrel  
for stroke reduction
Platelet aggregation inhibitors reduce the risk of non-fatal 
stroke by 23% (from 10.8% to 8.3% over 36 months) and 
all vascular events (nonfatal myocardial infarction, non-
fatal stroke, and vascular death) by 17% (from 21.4% to 
17.8% over 29 months) in patients after TIA or stroke.16 
Antiplatelet agents have different targets to prevent platelet 
activation and adhesion to the blood vessel wall or platelet 
aggregation finally resulting in thrombus formation. To 
date, ASA, the combination of aspirin (as the most common 
ASA) and extended-release dipyridamole and clopidogrel 
are most frequently used for long-term antiplatelet therapy 
in patients with non-cardioembolic stroke.17 Only aspirin has 
been shown to be safe and effective, both in the acute post-
ischemic phase (first 48 hours; 160 mg–300 mg/day) and in 
long-term secondary prevention.18 As a consequence, where 
possible, aspirin should be started immediately in patients 
with TIA or ischemic stroke after brain hemorrhage has been 
ruled out by brain imaging. Aspirin is effective irrespective 
of dose (30 mg–300 mg/day) in long-term secondary stroke 
prevention, but doses 150 mg/day are associated with more 
side effects, especially gastrointestinal adverse events and 
bleeding.16
It is a common clinical practice to combine different 
  antiplatelet agents to enhance their antiaggregation effect. The 
combination of aspirin 30–300 mg/day and extended-release 
dipyridamole 200 mg twice a day was shown to be more effec-
tive than aspirin alone in the ESPS-2 trial.19 A meta-analysis of 
five stroke prevention studies of aspirin alone versus aspirin-
dipyridamole in 7612 patients with TIA or minor stroke showed 
a relative risk reduction in favor of the combination therapy for 
a combined vascular endpoint (ischemic stroke, myocardial 
infarction, vascular death) of 18% (95% confidence interval 
[CI]: 8%–28%).20 The combination therapy was also more effec-
tive in preventing recurrent stroke alone. The clinically relevant 
side effect of headache in patients treated with dipyridamole 
can be reduced by slow titration and administration of dipyri-
damole. In the Prevention Regimen for Effectively Avoiding 
Second Strokes (PRoFESS) trial,21 the rate of permanent study 
discontinuation because of headache was 5.9% in the treatment 
arm receiving an aspirin-dipyridamole combination.
Clopidogrel 75 mg/day was compared with aspirin 
325 mg/day in 19,185 patients with stroke, myocardial 
infarction, or peripheral arterial disease (PAD) in the 
Clopidogrel versus Aspirin in Patients at Risk of Ischemic 
Events (CAPRIE) study.22 During a mean followup period of 
1.91 years, patients treated with clopidogrel had an annual 
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Figure 1 Mode of action of clopidogrel.
Clopidogrel irreversibly inhibits the ADP P2Y12 receptor. P2X1 mediates extracellular calcium influx and utilizes ATP as an agonist. The binding of ADP to the G-coupled P2Y12 
receptor liberates G protein subunits and results in stabilization of platelet aggregation. One subunit leads to inhibition of AC, which reduces cAMP levels. cAMP as well as the 
second subunit of the G protein lead to activation of the GP IIb/IIIa receptor.
Abbreviations: AC, adenylyl cyclase; ADP, adenosine diphosphate; ATP, adenosine triphosphate; Ca, calcium; cAMP, cyclic adenosine monophosphate; GDP, guanosine 
  diphosphate; GP, glycoprotein; GTP, guanosine triphosphate.Vascular Health and Risk Management 2010:6 98
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5.32% risk of ischemic stroke, myocardial infarction, or 
vascular death, compared with 5.83% in patients taking 
aspirin, resulting in a relative risk reduction of 8.7% (95% 
CI: 0.3–16.5). The greatest benefit of clopidogrel could be 
seen in patients with concomitant PAD.
Specific recommendations for antiplatelet therapy with 
clopidogrel can be made for patients who are allergic to 
aspirin and in patients at risk for stroke with PAD. In patients 
with a history of aspirin-induced ulcer bleeding, aspirin in 
combination with the proton-pump inhibitor (PPI) esome-
prazole was found to be superior to clopidogrel alone in the 
prevention of recurrent ulcer bleeding.23 The combination of 
PPIs with clopidogrel resulted in a significantly increased risk 
of death and rehospitalization for acute coronary syndrome 
in patients after an acute myocardial infarction, as shown in 
a recently published retrospective study in 8205 patients.24
A head-to-head comparison of clopidogrel versus the 
combination of aspirin 50 mg/day and extended-release 
dipyridamole 400 mg/day was made in the above-mentioned 
PRoFESS trial.21 This trial was the largest ever performed 
study of secondary stroke prevention, including 20,332 
patients with recent ischemic stroke. There was no significant 
difference in the rate of recurrent stroke (8.8% versus 9.0%), 
or in efficacy across all other secondary endpoints or sub-
group of patients after a mean followup period of 2.4 years. 
The aspirin-dipyridamole combination resulted in slightly 
more intracranial bleeds and a higher dropout rate because of 
headache compared with clopidogrel (5.9% versus 0.9%).
The  combination  of  aspirin-clopidogrel  is  not 
  recommended for long-term secondary stroke prevention 
because of an increased bleeding risk. The Management of 
Atherothrombosis with Clopidogrel in High-risk Patients with 
Recent TIA or Ischemic Stroke ( MATCH) trial compared the 
combination of clopidogrel 75 mg/day and aspirin 75 mg/day 
with clopidogrel monotherapy in 7599 high-risk patients with 
recent TIA/stroke, and failed to show superiority of combina-
tion therapy for the combined endpoint of stroke, myocardial 
infarction, vascular death, and hospitalization because of a 
vascular event.25 The combination resulted in a significant 
increase in life-threatening or major hemorrhage.
Similar to the results of the MATCH trial, the combined 
primary and secondary prevention Clopidogrel for High 
Atherothrombotic Risk and Ischemic Stabilization, Man-
agement, and Avoidance (CHARISMA) trial did not show 
a benefit for the combination of aspirin-clopidogrel over 
aspirin monotherapy. Again, bleeding rates were increased 
by the combination therapy.26 However, the subgroup of 
symptomatic patients with prior myocardial infarction, 
ischemic stroke, or symptomatic PAD showed a benefit from 
combination antiplatelet therapy,27 but this finding has to be 
confirmed in a prospective, randomized trial.
The Atrial Fibrillation Clopidogrel Trial with Irbesartan 
for Prevention of Vascular Events (ACTIVE) compared the 
addition of either clopidogrel 75 mg/day or placebo to aspirin 
75 mg–100 mg/day for use in patients with AF who were 
considered “unsuitable” for VKA therapy.28 ACTIVE A was 
one of three related studies of patients with AF, including 
ACTIVE W,29 a randomized comparison of a VKA versus 
a combination of clopidogrel- aspirin, and ACTIVE I, an 
ongoing, placebo-controlled study of irbesartan for patients 
enrolled in ACTIVE A or ACTIVE W. ACTIVE W was 
terminated early after showing that VKA therapy was more 
effective than the clopidogrel-aspirin combination in patients 
at high risk for stroke, confirming the superiority of this 
strategy.
ACTIVE A added to our understanding of the role of 
intensive antiplatelet therapy to prevent stroke in selected 
patients with AF. This large, randomized trial showed 
that the combination of clopidogrel-aspirin significantly 
reduced the rate of major vascular events (driven primarily 
by fewer strokes) compared with aspirin alone, in certain 
patients with AF. One disabling or fatal stroke would be 
prevented per approximately 200 patients treated for one 
year with a clopidogrel-aspirin combination. These effects 
were mostly consistent across subgroups, although there 
may be interactions with age, CHADS2 score (see Table), 
or previous use of a VKA. On the other hand, one extra 
major bleeding episode and one extra intracranial hemor-
rhage would occur per approximately 143 and 500 patients, 
respectively, treated for one year with a clopidogrel-aspirin 
combination.
The issue of to whom do the ACTIVE A results best 
apply cannot be completely answered at this point. Although 
the investigators intended to enroll patients who were ineli-
gible for anticoagulation therapy with VKAs, less than one 
quarter of participants had a documented contraindication 
to VKAs. Half were enrolled on the basis of a physician’s 
judgment that a VKA was not suitable for the patient; 
however, no strict case definition for “unsuitable” was 
used. Patient preference not to take a VKA was the reason 
given for enrollment of the approximately 25% remain-
ing participants, but there is evidence suggesting that this 
preference can be affected by how therapeutic options are 
presented to patients.
It is important to note that neither regimen studied in 
ACTIVE A is as effective as VKA therapy for the prevention Vascular Health and Risk Management 2010:6 99
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of ischemic stroke. The annual rates of stroke among 
participants receiving the clopidogrel-aspirin combination 
(2.4%) or aspirin alone (3.3%) were notably higher than 
those reported in patients at high risk for stroke who received 
VKA therapy (approximately 1.1%–1.3%). These high stroke 
rates were seen despite the fact that nearly 40% of ACTIVE 
A participants had a CHADS2 score of 0 or 1 (low predicted 
risk of stroke), and 34% had a CHADS2 score of 2 (moderate 
predicted risk of stroke). Although aspirin therapy, with or 
without clopidogrel, requires no dose adjustment or moni-
toring (two of the main drawbacks of VKAs), a surprisingly 
high percentage of patients discontinued therapy during the 
followup period (39% in the clopidogrel group and 37% in 
the placebo group). Adherence is usually worse in everyday 
clinical practice than in selected patients in carefully moni-
tored trial protocols, so the benefits seen with clopidogrel 
in ACTIVE A may not be achieved in “real-world” clinical 
populations.
Safety and tolerability
Several complications are common with all antiplatelet 
agents. Severe rash and diarrhea are more frequently asso-
ciated with clopidogrel than with aspirin. The incidence 
of hemorrhagic events is comparable between aspirin and 
clopidogrel. Gastrointestinal bleeding occurs with both agents. 
However, substitution of clopidogrel for aspirin in high-risk 
patients with recurrent ulcer bleeding is not recommended 
because it is inferior to treatment with aspirin and a PPI.23 
A serious but less frequent adverse reaction of clopidogrel is 
intracranial hemorrhage. Furthermore, clopidogrel is associ-
ated with thrombotic thrombocytopenic purpura.30 Rates of 
neutropenia and thrombotic thrombocytopenic purpura are 
similar between aspirin and clopidogrel. Thrombotic throm-
bocytopenic purpura occurs within the first two weeks of 
treatment. Ticlopidine, another thienopyridine, is associated 
with neutropenia in approximately 1% of patients, which is 
mostly reversible on discontinuation of therapy.31 However, 
in a few cases it is irreversible and potentially life-threatening. 
Patients must therefore be regularly monitored within the first 
three months of treatment. Clopidogrel is contraindicated in 
patients hypersensitive to ticlopidine, and in those with active 
gastrointestinal bleeding, acute hemorrhagic stroke or severe 
hepatic impairment.32
Clopidogrel is associated with an increased risk of serious 
bleeding complications. This potentially becomes a problem 
with patients undergoing percutaneous coronary intervention 
or bypass surgery. The risk of reoperation and requirement 
for blood transfusions during coronary artery bypass sur-
gery is increased.33 The concurrent use of clopidogrel with 
other platelet inhibitors, anticoagulants, fibrinolytics, or 
non-steroidal anti-inflammatory agents is associated with 
an increased incidence of bleeding. To reduce the risk for 
gastrointestinal bleeding, guidelines recommend the addon 
use of a PPI.34 However, a recent trial has shown that certain 
PPIs (namely omeprazole, lansoprazole, and rabeprazole) 
interfere with the activating metabolism of clopidrogrel.35 
This results in decreased antiplatelet activity of clopidogrel, 
and patients treated with one of these PPIs were at a signifi-
cant higher risk of readmission for MI.
The optimal antithrombotic treatment for patients with 
AF at medium or high thromboembolic risk who undergo 
percutaneous coronary intervention with stent implantation 
is currently undefined. Based on the scant available data, 
triple therapy consisting of VKA-aspirin-clopidogrel appears 
to offer the best protection against thromboembolic and 
myocardial ischemic events, at the price of an increased risk 
of serious hemorrhagic complications.36 The VKA-aspirin 
combination appears to be less effective, and therefore should 
not be prescribed in the early period following percutaneous 
coronary intervention with stent implantation.37 Whether 
the VKA-clopidogrel combination will preserve efficacy 
with less bleeding is an important and challenging question, 
but initial data support its use for several months after the 
early period of triple therapy for the prevention of recurrent 
coronary events.38
Table 1 CHADS2 score
C: Congestive heart failure = 1 point
H: Hypertension (systolic  160 mmHg) = 1 point
A: Age  75 years = 1 point
D: Diabetes = 1 point
S: Prior transient ischemic attack or stroke = 2 points
CHADS2 score Adjusted stroke rate* (%) [95% CI]
0 1.9 (1.2–3.0)
1 2.8 (2.0–3.8)
2 4.0 (3.1–5.1)
3 5.9 (4.6–7.3)
4 8.5 (6.3–11.1)
5 12.5 (8.2–17.5)
6 18.2 (10.5–27.4)
Notes:   The annual stroke rates for patients suffering from atrial fibrillation according 
to the CHADS2 Score. Patients with a CHADS2 Score of 0 are considered to have a 
low risk for cardioembolic stroke. Patients with a score of 1–2 are classified as having 
a moderate risk for stroke and should be medically treated with an antithrombotic 
agent. Patients with a score of 3 or higher have a high risk for thromboembolic com-
plications and require optimal antithrombotic treatment as well. *The adjusted stroke 
rate is the expected stroke rate per 100 person/years derived from the multivariable 
model assuming that aspirin is not taken.Vascular Health and Risk Management 2010:6 100
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The safe use of oral anticoagulation with VKAs depends 
on patient cooperation and a monitoring system that can 
achieve INR targets on a regular basis. Findings of the 
randomized trials suggest that anticoagulation at an INR of 
2.0–3.0 can be reasonably safe even for elderly patients, and 
the Italian Study on Complications of Oral Anticoagulant 
Therapy (ISCOAT) study39 and Anticoagulation and Risk 
Factors in Atrial Fibrillation (ATRIA) study40 studies demon-
strate that low hemorrhage rates can be achieved in clinical 
practice outside of trials, particularly if well organized health 
professionals are involved.
Patient considerations
The CHADS2 score is the best validated clinical predictor of 
risk of stroke and of who should be treated with antithrom-
botics.41 It assigns points (0–6) depending on the presence or 
absence of comorbidities (see Table 1). To compensate for the 
increased risk of stroke, anticoagulation may be necessary. 
However, with VKAs, if a patient with AF has a yearly risk 
of stroke of less than 2%, the risks associated with taking 
warfarin outweigh the risk of having a stroke. For patients 
with a lower risk for ischemic stroke, antiplatelet agents such 
as aspirin or clopidogrel can be prescribed.42
In addition to clinical risk stratification, patient perspec-
tives and preferences should be incorporated into the deci-
sion about the most suitable antithrombotic therapy. Prior 
studies have shown that patient and physician perspectives 
often differ, with patients, unlike physicians generally plac-
ing more value on stroke prevention than avoiding a major 
hemorrhage. Many patients, in fact, assign values to a mod-
erate to severe stroke that are equivalent to or worse than 
death.16 Ethnic and cultural differences in patient perception 
of AF and antithrombotic therapy are known to exist, and 
these differences can affect worldwide use of antithrombotic 
therapy in AF patients.43
Decision-analysis techniques have been used to evaluate 
the projected net benefit or harm associated with different 
antithrombotic treatment strategies in AF. These models 
formally combine the absolute risks associated with a number 
of patient characteristics, estimates of the efficacy and safety 
of antithrombotic treatment, and assigned values (utilities) of 
related health states (eg, taking warfarin, suffering a major 
stroke) trials. Sensitivity analyses test the impact of varying 
assumptions made in the model. In general, published decision 
analyses support the net benefit of anticoagulation with oral 
VKAs for patients with AF at moderate to high risk for stroke 
but not at very high risk of bleeding.44 However, the treatment 
threshold for these levels of risk and the criteria for moderate 
and high-risk categories vary across studies, reflecting the 
need for more refined estimates. The decision-analysis 
approach has been modified in attempts to help individual 
patients make better choices about antithrombotic therapy 
in AF.16 Strong evidence is currently lacking, however, that 
these decision support tools improve clinical outcomes.
Multiple  studies  of  practice  patterns  of  use  of 
  antithrombotic and antiplatelet therapy for AF have been 
reported. In North America and Western Europe the use of 
VKAs for AF has increased greatly from the early 1990s 
to the present. Currently, at least 50% of AF patients are 
treated with VKAs, and their use is moderately higher in 
patients at increased risk for ischemic stroke and moderately 
lower in patients at increased risk of bleeding. However, 
the use of VKAs decreases with age 80 years despite the 
fact that such patients are at higher risk of ischemic stroke. 
Many patients at apparently low risk for stroke are treated 
with VKAs and many patients at higher risk for stroke, eg, 
those who have a past history of ischemic stroke, are not 
treated with VKAs. Detailed clinical assessment of high-
risk patients not receiving VKA therapy shows that many of 
them have clear physical and/or cognitive contraindications 
to anticoagulants.45 In contrast with the generally aggressive 
use of anticoagulants for AF in North America and Western 
Europe, physicians in Japan are reluctant to prescribe VKAs 
for AF, presumably reflecting more concern about hemor-
rhagic stroke. When VKAs are prescribed in Japan, target 
INR levels are generally lower.46
For a long time oral VKAs were the most effective form 
of stroke prevention therapy in patients with AF. However, 
VKA therapy approximately doubles the risk of intracranial 
haemorrhage, is challenging to deliver in a high-quality fashion 
(ie, maintaining an international normalized INR ratio of 2.0 
to 3.0), and can diminish quality of life because of the need 
for frequent testing, dietary restrictions, and drug-drug interac-
tions.47 The situation is exacerbated by difficulties in predicting 
which patients are at highest risk for stroke and who are at 
highest risk for bleeding. As previously mentioned, preferences 
of physicians and patients may differ substantially with regard 
to the relative importance of avoiding ischemic stroke and 
avoiding bleeding complications. Collectively, these factors 
have contributed to marked variation in the use of different 
antithrombotic agents for patients with AF and have fueled the 
pursuit of alternative stroke prevention strategies.
As a result, patient education and involvement in the 
anticoagulation decision is important. Many patients with AF 
have a fear of ischemic stroke and choose a VKA despite the 
relatively small decrease in the absolute risk of stroke, while Vascular Health and Risk Management 2010:6 101
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others at relatively low risk of stroke are likely to want to 
avoid the burden and risks of VKA therapy and so opt instead 
for antiplatelet agents, such as clopidogrel or aspirin.
Conclusions
Fifteen years after the publication of multiple definitive trials 
demonstrating the efficacy of anticoagulants in preventing 
stroke in patients with AF and more recent evidence from 
large and rigorous trials which have validated both the 
efficacy and safety of anticoagulants in AF, there remains 
considerable controversy about which patients with AF 
should be treated with long-term VKA and those who should 
receive antiplatelet therapy.
Indeed, some recent revised guidelines have become 
more restrictive in recommending anticoagulant therapy 
for patients with AF. However, ASAs (such as aspirin) are 
the most widely used antiplatelet agents in patients with 
AF who are at risk for stroke. For patients who develop 
TIA/stroke on ASA therapy, the options are to increase 
the ASA dosage, to add another antiplatelet agent, to 
switch to another antiplatelet agent, or to switch to another 
antiaggregation agent such as a VKA or direct thrombin 
inhibitor (dabigatran being the only approved agent for this 
indication to date). One proposed approach is to combine 
antiplatelet agents with different modes of action, such as 
ASA and clopidogrel, to achieve a better antithrombotic 
effect. Several trials, including PRoFESS, MATCH and 
CHARISMA21,25,26 addressed this issue. None of these trials 
demonstrated a clear benefit of a combination therapy of 
antiplatelet agents over monotherapy. Furthermore, bleed-
ing rates were increased with all combination therapies. 
In patients with AF and a lower risk for stroke who are 
intolerant of ASAs, clopidogrel can be a useful alterna-
tive, especially when the risk of hemorrhage is potentially 
increased by VKA therapy.
Approximately a third of patients with AF also have a 
diagnosis of coronary artery disease.16 These patients face 
a sizable risk of future coronary events as well as stroke. For 
those individuals who are receiving anticoagulants to prevent 
stroke, it is unclear if an ASA and/or clopidogrel should be 
added to prevent coronary events and stroke more effectively. 
There are no randomized trials that directly address this issue. 
Decisions on optimal antithrombotic and antiplatelet therapy 
need to be made individually, taking into consideration the 
severity of coronary artery disease, stent implantation, and 
risk of stroke.
To further optimize stroke prevention in patients with 
AF, more reliable methods to predict the individual risk of a 
patient having an ischemic stroke and bleeding (especially 
intracranial hemorrhage) need to be identified. Physicians 
should consistently apply existing data to identify patients 
eligible for either VKA or antiplatelet therapy, and should 
present a complete and balanced picture of the absolute 
risks and benefits of each approach to the patient to enable 
informed decision-making. To date, current evidence sup-
ports the view that patients with AF at moderate-to-high risk 
(estimated favorably with the CHADS2 score) for stroke, and 
for whom a VKA is suitable, should be considered for this 
therapy to maximize the prevention of thromboembolism 
with an acceptable risk of major bleeding. For patients with 
AF who are at moderate-to-high risk for stroke but who are 
not suitable for VKA therapy, and in whom high-quality 
anticoagulation is not achieved despite the best efforts, or 
those who are at lower risk for stroke, the combination of 
clopidogrel-aspirin will most likely provide more clinical 
benefit than aspirin alone.
As mentioned earlier, the RE-LY trial10 has the potential 
to change the landscape of stroke prevention in patients with 
AF. The advantages of treatment with an orally available 
direct thrombin inhibitor such as dabigatran are obvious. 
Dabigatran more closely meets the criteria for optimal anti-
thrombotic efficacy and has the ability to improve quality 
of care. Such an advance might also help to overcome the 
gaps between evidence-based treatment recommendations 
and clinical practice. Dabigatran has proven to be highly 
effective in reducing venous thromboembolism,48 inhibiting 
both free and clot-bound coagulation factors. Furthermore, 
it has a predictable dose response and kinetics, and shows 
low, non-specific plasma protein binding, resulting in a low 
rate of bleeding events. Coagulation monitoring and dose 
adjustment is not routinely required, thus creating a wide 
therapeutic window. Furthermore, there is little interaction 
with food or other medicines.49 Overall, newly developed 
and orally available direct thrombin inhibitors and/or Factor 
Xa inhibitors may reduce the role of antiplatelet agents such 
as clopidogrel, as well as VKAs such as warfarin, and over-
come obstacles of current antithrombotic strategies in stroke 
prevention for patients suffering from AF.
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